High-Risk Melanoma: Dabrafenib/Trametinib Preserves Quality of Life While Preventing Relapse

Previously, the researchers of the phase 3 COMBI-AD study found that adjuvant combination therapy consisting of dabrafenib (Taflinar®, Novartis) plus trametinib (Mekinist®, Novartis) helped to prevent relapse in patients with high-risk BRAF V600–mutant melanoma after surgical resection. The investigators now report that dabrafenib/trametinib combination therapy also helps to maintain quality of life. A targeted therapy drug, trametinib is an MEK inhibitor that works by targeting the MEK 1 and ME...
Continue reading

Rigosertib Provides Hope in Patients With Butterfly Disease

For many patients with the genetic disease recessive dystrophic epidermolysis bullosa (RDEB), also known as butterfly disease, developing squamous cell carcinoma (SCC) by early adulthood is inevitable. Researchers teamed together and found a potential targeted treatment for patients with RDEB and SCC. "We hope that the drug will be a cure for the cancer," remarked one of the authors of the study, Andrew South, PhD, Associate Professor in the Department of Dermatology and Cutaneous Biology at Tho...
Continue reading

New Therapeutic Target for Melanoma Brain Metastases

Almost half of patients with malignant melanoma develop metastases in different organs, with 60% of metastases spreading to the brain. Once the cancer metastasizes, the 5-year survival rate plummets to 5% to 19%. Metastasized malignancies are resistant to current immunotherapies and targeted therapies; however, researchers at the University of Texas MD Anderson Cancer Center discovered that oxidative phosphorylation (OXPHOS) can be a potential treatment target. "Brain metastases are increasingly...
Continue reading

Pembrolizumab Approved for Resected Stage III Melanoma

​ The FDA has approved pembrolizumab (Keytruda®, Merck) for treatment of patients with melanoma experiencing lymph node involvement following complete resection. The approval was based on EORTC1325/KEYNOTE‑054 (NCT02362594), a phase 3 clinical trial which enrolled 1,019 patients with completely resected stage III melanoma with negative margins, lymph node dissection, and completion of radiotherapy, if indicated, within 13 weeks prior to treatment. Patients were randomly assigned in a 1:1 ratio, ...
Continue reading

In Melanoma, Smoking Impacts Antitumor Immune Response

The immune system's response to melanoma both improves survival for untreated patients and predicts a patient's response to immune checkpoint blockade therapy. A British study has now identified several genetic factors that can be used to predict a patient's immune response to melanoma. The study has also identified a significant environmental cause of lowered antitumor immunity: cigarette smoking. For the study, published in Cancer Research , investigators used a bioinformatic analysis of 703 t...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.